Ning Bo-Tao, Tang Yong-Min, Chen Ying-Hu, Shen Hong-Qiang, Qian Bai-Qin
Department of Hematology and Oncology, The Children's Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):943-7.
In order to provide the evidences for CD19 as a better antibody targeting molecule for B lineage acute leukemias than CD20 through the multi-parameter flow-cytometry analysis of leukemia cells, the samples from 321 patients with acute leukemia (AL) were immunophenotyped by multi-color flow cytometry and CD45/SSC gating strategy followed by the analysis of CD19 and CD20 expression. The results showed that the positive rate of CD19 (115/116, 99.1%) in 116 cases with B lineage acute lymphoblastic leukemia (B lineage ALL) was significantly higher than that of CD20 (33/116, 28.4%) (P < 0.01); in 17 patients with B lineage/Myeloid (B/My) acute mixed lineage leukemia (AMLL), the former positive rate (17/17, 100%) was also higher than the latter (5/17, 29.4%) (P < 0.01). Both of the two antigens were negative in 29 patients with acute T lymphoblastic leukemia and 7 patients with T/My AMLL. The positive rates of CD19 and CD20 in 152 patients with acute myeloid leukemia (AML) were 7.2% and 2.0%, respectively. The difference of the fluorescence intensity between the two antigens on the cells from each patient with B lineage ALL or B/My AMLL was statistically significant (t = 20.68, P < 0.001). The specificity of CD19 and CD20 in B lymphocytic lineage was 92.3% (132/143) and 92.7% (38/41), respectively, while the sensitivity was 99.2% (132/133) and 28.6% (38/133), respectively, the former sensitivity was significantly higher than the latter (chi(2) = 144.018, P = 0.001). It is concluded that CD19 continuously and steadily express on almost all subtypes of B lineage leukemic cells with homogeneous pattern while only a small number of leukemias express CD20. Both the specificity and sensitivity of CD19 were very high with a much broader reaction pattern than that of CD20 on this group of diseases. These indicate that CD19 may be a better antibody targeting molecule than CD20 for patients with B-lineage acute leukemia.
为了通过白血病细胞的多参数流式细胞术分析，提供CD19作为比CD20更适合B系急性白血病的抗体靶向分子的证据，采用多色流式细胞术和CD45/SSC设门策略对321例急性白血病（AL）患者的样本进行免疫表型分析，随后分析CD19和CD20的表达情况。结果显示，116例B系急性淋巴细胞白血病（B系ALL）患者中CD19的阳性率（115/116，99.1%）显著高于CD20的阳性率（33/116，28.4%）（P<0.01）；17例B系/髓系（B/My）急性混合细胞白血病（AMLL）患者中，前者的阳性率（17/17，100%）也高于后者（5/17，29.4%）（P<0.01）。29例急性T淋巴细胞白血病患者和7例T/My AMLL患者的这两种抗原均为阴性。152例急性髓系白血病（AML）患者中CD19和CD20的阳性率分别为7.2%和2.0%。各B系ALL或B/My AMLL患者细胞上这两种抗原的荧光强度差异具有统计学意义（t=20.68，P<0.001）。B淋巴细胞系中CD19和CD20的特异性分别为92.3%（132/143）和92.7%（38/41），而敏感性分别为99.2%（132/133）和28.6%（38/133），前者敏感性显著高于后者（χ2=144.018，P=0.001）。结论是，CD19在几乎所有B系白血病细胞亚型上持续稳定表达，呈均匀模式，而只有少数白血病表达CD20。在这组疾病中，CD19的特异性和敏感性都非常高，反应模式比CD20广泛得多。这些表明，对于B系急性白血病患者，CD19可能是比CD20更好地抗体靶向分子。
